Laboratorios Farmaceuticos Rovi, S.A. (LABFF) 📈: анализ компании, ее дивидендная стратегия и оценка мультипликаторов, прогноз цены и инвестиционные идеи для Laboratorios Farmaceuticos Rovi, S.A.

1. Summary

Advantages

Dividends (2.75%) are higher than the sector average (1.7%).
The stock's return over the last year (0%) is higher than the sector average (-29.1%).
Current debt level 13.75% is below 100% and has decreased over 5 years from 16.57%.
The company's current efficiency (ROE=25.83%) is higher than the sector average (ROE=14.51%)

Disadvantages

Price (90.61 $) is higher than fair price (53.81 $)

Similar companies

WuXi Biologics (Cayman) Inc.

Roche Holding

Sino Biopharmaceutical Limited

Sinopharm Group Co., Ltd.

2. Share price and performance

2.1. Share price

2.3. Market efficiency

	Laboratorios Farmaceuticos Rovi, S.A.	Healthcare	Index
7 days	0%	-38.9%	0%
90 days	0%	-36.4%	3.6%
1 year	0%	-29.1%	17.4%

LABFF vs Sector: Laboratorios Farmaceuticos Rovi, S.A. has outperformed the "Healthcare" sector by 29.1% over the past year.

LABFF vs Market: Laboratorios Farmaceuticos Rovi, S.A. has significantly underperformed the market by -17.43% over the past year.

Stable price: LABFF is not significantly more volatile than the rest of the market on "OTC" over the last 3 months, with typical variations of +/- 5% per week.

Long period: LABFF with weekly volatility of 0% over the past year.

3. Summary of the report

3.1. General

P/E: 32.61

P/S: 5.84

More data on LABFF

3.2. Revenue

EPS	3.1
ROE	25.83%
ROA	17.6%
ROIC	0%
Ebitda margin	27.2%

More data on LABFF

5. Fundamental Analysis

5.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Above fair price: The current price (90.61 $) is higher than the fair price (53.81 $).

Price is higher than fair: The current price (90.61 $) is 40.6% higher than the fair price.

5.2. P/E

P/E vs Sector: The company's P/E (32.61) is lower than that of the sector as a whole (45.46).

P/E vs Market: The company's P/E (32.61) is lower than that of the market as a whole (45.03).

5.2.1 P/E Similar companies

5.3. P/BV

P/BV vs Sector: The company's P/BV (7.68) is higher than that of the sector as a whole (5.31).

P/BV vs Market: The company's P/BV (7.68) is higher than that of the market as a whole (4.36).

5.3.1 P/BV Similar companies

5.5. P/S

P/S vs Sector: The company's P/S indicator (5.84) is higher than that of the sector as a whole (4.3).

P/S vs Market: The company's P/S indicator (5.84) is lower than that of the market as a whole (12.87).

5.5.1 P/S Similar companies

5.5. EV/Ebitda

EV/Ebitda vs Sector: The company's EV/Ebitda (21.91) is higher than that of the sector as a whole (17.43).

EV/Ebitda vs Market: The company's EV/Ebitda (21.91) is lower than that of the market as a whole (23.89).

6. Profitability

6.1. Profitability and revenue

6.2. Earnings per share - EPS

6.3. Past profitability Net Income

Yield Trend: Rising and has grown by 38.71% over the last 5 years.

Earnings Slowdown: The last year's return (-1.49%) is below the 5-year average return (38.71%).

Profitability vs Sector: The return for the last year (-1.49%) is lower than the return for the sector (-1.46%).

6.4. ROE

ROE vs Sector: The company's ROE (25.83%) is higher than that of the sector as a whole (14.51%).

ROE vs Market: The company's ROE (25.83%) is lower than that of the market as a whole (50.88%).

6.6. ROA

ROA vs Sector: The company's ROA (17.6%) is higher than that of the sector as a whole (7.45%).

ROA vs Market: The company's ROA (17.6%) is lower than that of the market as a whole (35.83%).

6.6. ROIC

ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (14.14%).

ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (10.8%).

7. Finance

7.1. Assets and debt

Debt level: (13.75%) is quite low in relation to assets.

Debt reduction: over 5 years, the debt has decreased from 16.57% to 13.75%.

Debt Covering: The debt is covered by 83.6% from net profit.

7.2. Profit growth and share price

8. Dividends

8.1. Dividend yield vs Market

High yield: The dividend yield of the company 2.75% is higher than the average for the sector '1.7%.

8.2. Stability and increase in payments

Dividend stability: The company's dividend yield 2.75% has been steadily paid over the past 7 years, DSI=0.83.

Weak dividend growth: The company's dividend yield 2.75% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

8.3. Payout percentage

Dividend Coverage: Current payments from income (41.24%) are at a comfortable level.

Investing Port

Laboratorios Farmaceuticos Rovi, S.A.

Company Analysis Laboratorios Farmaceuticos Rovi, S.A.